Compare iShares MSCI Hong Kong ETF (EWH) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $21.93 (market cap $1.16B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: iShares MSCI Hong Kong ETF is far larger — about 17.1× Heron Therapeutics Inc's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Heron Therapeutics Inc for 35 Days on average.
| EWH | HRTX | |
|---|---|---|
Market Cap | $1.16B | $68.01M |
Volume | 3,176,523 | 1,891,941 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $1.49 |
52-Week Low | $20.66 | $0.27 |
Typical Hold Time | 61 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.58, down 0.19% today amid bearish technical signals with moving averages indicating strong selling pressure. The ETF tracks Hong Kong equities, which have faced volatility due to Federal Reserve policy and US-Iran tensions, as reflected in recent Hang Seng Index declines. Key support sits at $21 with resistance clustered around $22. Financial ratios are unavailable in the current dataset.
Outlook remains cautious given bearish technicals and macroeconomic headwinds impacting Hong Kong markets. Opportunities exist if geopolitical tensions ease and technology stocks rebound, but risks include prolonged Fed tightening and China economic struggles. Investors should monitor Hang Seng Index momentum and institutional flow trends for directional cues.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
